billHR6624Event Wednesday, April 22, 2026Analyzed

Biological Intellectual Property Protection Act of 2025

Neutral
Impact5/10

Summary

HR6624 forces a structural onshoring of U.S. synthetic biology IP and manufacturing away from PRC entities. Domestic pure-plays Ginkgo Bioworks ($DNA) and Twist Bioscience ($TWST) are direct beneficiaries, while large biopharma Amgen ($AMGN) and Regeneron ($REGN) face near-term capex pressure but reduced long-term IP risk. The bill advanced out of committee with bipartisan support and has an identical Senate companion bill, increasing passage probability.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR6624 forces onshoring of synthetic biology IP and manufacturing away from PRC entities; no direct spending, but massive supply chain restructuring
  • 2.Domestic pure-plays $DNA (Ginkgo Bioworks) and $TWST (Twist Bioscience) are direct structural beneficiaries
  • 3.Large biopharma $AMGN and $REGN face near-term capex pressure but gain long-term IP protection; neutral with downside risk on execution
  • 4.Bipartisan support and a Senate companion bill increase passage probability; floor vote likely within weeks

Market Implications

The bill is a catalyst for the U.S. synthetic biology sector. $DNA at $8.07 with a 30-day gain of 31.48% has already priced in partial expectation, but full passage could drive further multiple expansion as order volume from redirected biopharma spending materializes. $AMGN at $348.89 and $REGN at $706.58 are pricing in the capex headwind—watch for floor action as a binary event that could widen the spread between pure-plays and diversified biopharma. For retail investors, the clearest play is $DNA as a high-conviction beneficiary with direct revenue impact from onshoring orders.

Full Analysis

On April 22, 2026, the House Foreign Affairs Committee ordered HR6624, the Biological Intellectual Property Protection Act of 2025, reported out on a 30-14 vote. The bill, sponsored by Rep. Davidson (R-OH) with 11 cosponsors including both Republicans and Democrats, restricts export of U.S. synthetic biology intellectual property and sensitive information to PRC entities. It now awaits a floor vote in the House. An identical companion bill, S3452, has been introduced in the Senate, signaling bipartisan coalition building. The bill is an authorization bill—it sets policy and trade restrictions but does not appropriate funding. The mechanism is an export control: it prohibits transfer of synthetic biology IP and sensitive data to PRC-linked entities. There is no direct government spending allocation; the economic impact comes from forced restructuring of private sector supply chains. Structural winners are domestic synthetic biology pure-play companies. Ginkgo Bioworks ($DNA) at $8.07 has rallied 31.48% in the last 30 days, reflecting market anticipation of this shift. Twist Bioscience ($TWST), though not provided in the market data here, is similarly positioned as a U.S.-based DNA synthesis leader. Both companies gain strategic value as compliant domestic alternatives to PRC-based CDMOs. Structural laggards are large biopharma companies with PRC-linked manufacturing or R&D partnerships. Amgen ($AMGN) at $348.89 (30-day -0.84%) and Regeneron ($REGN) at $706.58 (30-day -8.55%) face near-term capital expenditure pressure to onshore or nearshore production. However, both benefit from reduced IP theft risk and supply chain security long-term, which supports earnings stability. Legislative timeline: the bill must pass the full House, then the Senate (where identical S3452 awaits committee action), then be signed by the President. Given bipartisan support and a committee vote with only 14 nays, passage probability is elevated but not guaranteed. Floor action could occur within weeks.

Intelligence Surface

Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures

Unconfirmed

No confirming evidence found yet from contracts, insider trades, or congressional activity

$$DNA▲ Bullish
Est. $50.0M$200.0M revenue impact

What the bill does

Export restriction on U.S. synthetic biology IP and sensitive information to PRC entities; creates structural barrier to PRC-based CDMO partnerships

Who must act

U.S. biopharma companies and CDMOs currently sourcing synthetic biology services or transferring IP to PRC-linked entities

What happens

U.S. biopharma must onshore or nearshore synthetic biology R&D and production, increasing demand for domestic pure-play platform providers

Stock impact

Ginkgo Bioworks ($DNA) is a U.S.-based synthetic biology pure-play with cell programming platform revenue; immediate strategic value as a compliant, domestic alternative to PRC-based CDMOs. 30-day +31.48% price momentum reflects market pricing in this demand shift.

$$TWST▲ Bullish
Est. $30.0M$120.0M revenue impact

What the bill does

Export restriction on U.S. synthetic biology IP and sensitive information to PRC entities; restricts DNA synthesis and gene-editing service transfers

Who must act

U.S. biopharma and research institutions using PRC-based gene synthesis or DNA manufacturing services

What happens

Shift of DNA synthesis orders to U.S.-based providers, increasing domestic order volume and pricing power

Stock impact

Twist Bioscience ($TWST) is a U.S. pure-play DNA synthesis provider with Silicon Valley manufacturing; directly captures orders redirected from PRC competitors. Not provided in real market data, but structurally positioned as beneficiary.

Market Impact Score

5/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

presidential_memorandumApr 20, 2026

Presidential Determination Pursuant to Section 303 of the Defense Production Act of 1950, as Amended, on Grid Infrastructure, Equipment, and Supply Chain Capacity

This Presidential Memorandum invokes Section 303 of the Defense Production Act (DPA) to address critical deficiencies in the domestic electric grid infrastructure and its supply chains. It authorizes the Secretary of Energy to make purchases, commitments, and provide financial support to expand the domestic capacity for designing, producing, and deploying grid infrastructure components like transformers, transmission lines, and related manufacturing tools, waiving certain DPA requirements for expediency.

presidential_memorandumApr 20, 2026

Presidential Determination Pursuant to Section 303 of the Defense Production Act of 1950, as Amended, on Development, Manufacturing, and Deployment of Large-Scale Energy and Energy‑Related Infrastructure

This presidential memorandum invokes Section 303 of the Defense Production Act (DPA) to accelerate the development, manufacturing, and deployment of large-scale energy and energy-related infrastructure. It authorizes the Secretary of Energy to make necessary purchases, commitments, and financial instruments to expand domestic capabilities in this sector, citing a national energy emergency and the need to avert an industrial resource shortfall.

presidential_memorandumApr 20, 2026

Presidential Determination Pursuant to Section 303 of the Defense Production Act of 1950, as Amended, on Natural Gas Transmission, Processing, Storage, and Liquefied Natural Gas Capacity

This presidential memorandum invokes Section 303 of the Defense Production Act (DPA) to expand natural gas and LNG capacity, including pipelines, processing, storage, and export facilities. It directs the Secretary of Energy to implement this determination, including making necessary purchases, commitments, and financial instruments to enable these projects, citing national defense and allied energy security as critical needs.